Globalisation
The pharmaceutical sector is featured by a dynamic global market, with high perspectives of growth: increase of population, unsatisfied medical needs and commercialization of innovative products.
The sector has been highly internationalized and dominated by major world groups, as a result of operations of mergers and acquisition.
However, the pharmaceutical groups have to face new constraints:
- Product segmentation is more and more significant: generalization of generic drugs, development of medicines thanks to the innovation in biotechnologies;
- Increasing pressure on the cost prices due to the Indian and Chinese competitors;
- High level requirements of the regular authority ;
- Growing forgery represents relevant losses;
- Public policies reduce investment in the healthcare sector.
The economic model of laboratories is more and more threatened: the drug prices are decreasing whereas the R&D, marketing and production expenses are steadily increasing (intensification of regulatory constraints, high cost of biotechnology, etc).
In this context, the stakes for the laboratories are multiple:
- Continuing product innovation in order to develop new high potential molecules, which will allow balancing the development of generic;
- Improving the operational performance throughout the chain: reduction of the working capital, centralization of the purchase functions, optimization of the forecasts and stocks, optimization of the industrial schemes and operational performance;
- Developing the traceability to face forgery: homogenization of standards, introduction of tracking tools.
Assystem Consulting works with key players in the pharmaceutical sector in order to ensure the implementation of major industrial programs.
The Assystem group is our partner in all your missions in life sciences, through its Life Sciences activity. For more information, visit the website Assystem Life Sciences (in french).
